ZTlido (lidocaine) Patch Won FDA Approval For The Treatment Of Postherpetic Neuralgia

FDA Approves Scilex Pharmaceuticals’s ZTlido (lidocaine) For The Treatment Of Postherpetic Neuralgia

Company: Scilex Pharmaceuticals, Inc.

Brand Name: ZTlido

Generic Name: lidocaine

Dosage Form: Patch

Previous Name: Ztilido

Treatment for: Postherpetic Neuralgia

General information about ZTlido

ZTlido (lidocaine topical system 1.8%) is a transdermal anesthetic formulation for the treatment of pain associated with post-herpetic neuralgia ("PHN"), a severe neuropathic pain condition.

ZTlido is a single-layered anhydrous patch featuring proprietary technology that offers advantages over the multi-layered hydrogel patches. Containing only 36 mg of lidocaine per patch, compared to the 700 mg found in the multi-layered hydrogel system, ZTlido 1.8% patches use a specialized construction that makes them thinner, more adhesive and more flexible, with a rate-controlling membrane designed for more effective lidocaine delivery.

• Prev
• Next